OCGN

Ocugen Inc

0.7027

Oct 30 • 3:59 PM ET -0.0415 (-5.58%)

0.7340

Aftermarket • 6:02 PM ET +0.0313 (4.45%)

Healthcare Biotechnology USA Micro NASD

Peers: IRD MGTX RGNX FDMT BLTE PRQR QURE KOD ARCT NVAX

| Held by: VTI XBI IWM VXF VTWO IWO KOMP VHT IWC IWN

Scroll to Statements

Index	RUT
Market Cap	238.30M
Enterprise Value	226.24M
Income	-81.81M
Sales	4.58M
Book/sh	-0.05
Cash/sh	0.30
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	116
IPO	Dec 03, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	52.03
P/B	-
P/C	2.38
P/FCF	-
EV/EBITDA	-
EV/Sales	49.40
Quick Ratio	0.80
Current Ratio	0.80
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / No

EPS (ttm)	-0.25
EPS next Y	-0.27
EPS next Q	-0.06
EPS this Y	-12.32%
EPS next Y	-4.52%
EPS next 5Y	50.74%
EPS past 3/5Y	17.64% 5.89%
Sales past 3/5Y	21.05% 152.94%
EPS Y/Y TTM	-28.98%
Sales Y/Y TTM	-3.66%
EPS Q/Q	-45.35%
Sales Q/Q	8.38%
Earnings	Nov 04 BMO
EPS/Sales Surpr.	-31.33% 67.42%

Insider Own	2.34%
Insider Trans	-11.50%
Inst Own	46.16%
Inst Trans	11.30%
ROA	-92.03%
ROE	-660.00%
ROIC	-
Gross Margin	43.36%
Oper. Margin	-1504.43%
Profit Margin	-1786.27%
SMA20	-16.91%
SMA50	-32.04%
SMA200	-50.79%
Trades

Shs Outstand	339.04M
Shs Float	331.18M
Short Float	32.36%
Short Ratio	16.64
Short Interest	107.16M
52W High	2.72 -74.21%
52W Low	0.70 0.16%
Volatility	8.11% 7.19%
ATR (14)	0.06
RSI (14)	28.52
Beta	2.00
Rel Volume	0.84
Avg Volume	6.44M
Volume	5,406,926

Perf Week	-5.00%
Perf Month	-29.73%
Perf Quarter	-43.78%
Perf Half Y	-60.96%
Perf YTD	-47.95%
Perf Year	-52.52%
Perf 3Y	95.19%
Perf 5Y	-94.07%
Perf 10Y	-99.52%
Recom	1.00
Target Price	12.17
Prev Close	0.74
Price	0.70
Change %	-5.58%

Consensus

Strong Buy

Avg. Price Target

$12.17

Implied Upside

+1,631.9%

Analysts9incl. previous ratings

Rating Distribution9 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Mar 17, 2026	Initiated	CCanaccord Genuity	Buy	$12	+1,607.7%
Mar 11, 2026	Initiated	OOppenheimer	Outperform	$10	+1,323.1%
Oct 15, 2024	Initiated	MMaxim Group	Buy	$4	+469.2%
Mar 01, 2023	Upgrade	CChardan Capital Markets	Neutral → Buy	$3.50	+398.1%
Aug 23, 2022	Initiated	MMizuho	Buy	$5	+611.5%
Jun 15, 2022	Resumed	RROTH Capital	Buy	$8	+1,038.5%
Jun 02, 2022	Initiated	CCantor Fitzgerald	Overweight	$4.50	+540.4%
Jul 26, 2021	Initiated	NNoble Capital Markets	Outperform
Jun 11, 2021	Downgrade	RROTH Capital	Buy → Neutral	$10 → $6	+753.8%
May 07, 2021	Downgrade	CCantor Fitzgerald	Overweight → Neutral
Feb 09, 2021	Downgrade	CChardan Capital Markets	Buy → Neutral	$0.70 → $13	+1,750.0%
Feb 04, 2021	Upgrade	HH.C. Wainwright	Neutral → Buy	$4.50	+540.4%

Oct-29-26 07:02AM	Ocugen to Participate in Upcoming November Investor and Industry Conferences (GlobeNewswire)
Oct-27-26 02:28PM	Ocugen Heads Into Q3 Needing Proof Its GA Phase 3 Launch And 2028 Runway Hold (Earnings Whispers) +6.92%
Oct-22-26 07:00AM	Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4 (GlobeNewswire)
Oct-14-26 06:30AM	Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa (GlobeNewswire)
Oct-08-26 02:49PM	Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
07:02AM	Loading…
Oct-06-26 07:02AM	Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate (GlobeNewswire)
Sep-30-26 07:02AM	Ocugen to Participate in Upcoming Scientific Conferences (GlobeNewswire) -5.50%
Sep-29-26 07:02AM	Ocugen to Participate in Upcoming October Investor and Industry Conferences (GlobeNewswire) +5.83%
Sep-25-26 08:51AM	Ocugen Eyes Global Access For Gene Therapy After Bahamas Boost First Eye Disorder Patient Could Be Treated Within 90 Days (Stocktwits)
07:02AM	Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa (GlobeNewswire)
Sep-01-26 07:02AM	Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (GlobeNewswire)
Aug-25-26 07:02AM	Ocugen to Participate in Upcoming September Investor and Industry Conferences (GlobeNewswire)
Aug-06-26 07:15PM	Ocugen Inc (OCGN) (Q2 2026) Earnings Call Highlights: FDA Clearance for OCU410 Phase 3 Trial ... (GuruFocus.com)
07:22AM	Ocugen: Q2 Earnings Snapshot (Associated Press)
07:02AM	Ocugen Provides Business Update with Second Quarter 2026 Financial Results (GlobeNewswire)
07:02AM	Loading…
Jul-31-26 07:02AM	Ocugen to Participate in Upcoming August Investor Conferences (GlobeNewswire)
Jul-29-26 07:01AM	Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration (GlobeNewswire)
Jul-28-26 04:01PM	Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-13-26 07:02AM	Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa (GlobeNewswire)
Jul-01-26 07:00AM	Ocugen to Participate in Upcoming July Industry Conferences (GlobeNewswire)
Jun-02-26 07:03AM	Ocugen to Participate in Upcoming June Investor and Industry Conferences (GlobeNewswire)
May-14-26 04:30PM	Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes (GlobeNewswire)
May-13-26 07:02AM	Ocugen to Participate in Upcoming May Scientific and Investor Conferences (GlobeNewswire)
May-05-26 08:40AM	Ocugen: Q1 Earnings Snapshot (Associated Press) -19.46%
08:32AM	Ocugen Provides Business Update with First Quarter 2026 Financial Results (GlobeNewswire)
08:12AM	Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes (GlobeNewswire)
May-04-26 04:01PM	Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes (GlobeNewswire)
Apr-29-26 07:02AM	Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results (GlobeNewswire)
Apr-23-26 07:02AM	Ocugen to Present at April 2026 Investor and Industry Conferences (GlobeNewswire)
Apr-10-26 09:55AM	Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells (PR Newswire) -5.88%
07:02AM	Loading…
Apr-01-26 07:02AM	Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease (GlobeNewswire)
Mar-27-26 04:00AM	Can Ocugen succeed where other gene therapy makers have struggled? (Pharma Voice)
Mar-25-26 09:08AM	Ocugens GA gene therapy garners mixed sentiments on 12-month Phase II readout (Clinical Trials Arena)
Mar-24-26 07:45AM	Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (GlobeNewswire) -8.57%
Mar-23-26 07:02AM	Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410-Modifier Gene Therapy for Geographic Atrophy (GlobeNewswire)
Mar-11-26 06:10AM	Ocugen price target raised to $22 from $15 at Lucid Capital (TipRanks) +29.94%
Mar-10-26 09:40AM	Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? (Zacks) +6.63%
Mar-04-26 10:36AM	Ocugen Q4 Earnings Call Highlights (MarketBeat) +5.38%
09:25AM	Ocugen (OCGN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:32AM	Ocugen: Q4 Earnings Snapshot (Associated Press Finance)
08:15AM	Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-03-26 09:00AM	Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone (PR Newswire)
Mar-02-26 07:02AM	Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa (GlobeNewswire) +6.59%
Feb-25-26 07:25PM	Alector (ALEC) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-24-26 09:40AM	Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Miss Estimates (Zacks) +8.54%
Feb-18-26 07:02AM	Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-13-26 08:20AM	Moderna (MRNA) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-09-26 07:02AM	Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer (GlobeNewswire)
Jan-23-26 08:00AM	Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock (GlobeNewswire)
Jan-21-26 04:37PM	Ocugen (OCGN) Stock Tumbles After $22.5 Million Share Offering (Benzinga) -10.78% +10.74%
08:32AM	Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock (GlobeNewswire)
Jan-16-26 12:07PM	Ocugen Stock Is Surging Today: What's Driving The Action? (Benzinga)
Jan-15-26 01:15PM	Ocugen's Early Gene Therapy Data Shows 46% Drop In Vision Damage (Benzinga) -13.83%
12:30PM	OS Therapies Bone Cancer Trial Data Strengthens FDA Case (Benzinga)
08:15AM	Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (GlobeNewswire)
Jan-14-26 08:19AM	Novavax (NVAX) Moves 11.9% Higher: Will This Strength Last? (Zacks)
Jan-13-26 07:00AM	Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data (GlobeNewswire) +7.30%
Jan-12-26 06:30AM	Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy (GlobeNewswire) +18.67%
Jan-09-26 07:02AM	Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference (GlobeNewswire)
Dec-29-25 09:53AM	Ocugen Stock Surges 75% Year to Date: What's in Store for 2026? (Zacks)
Dec-16-25 09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks) +7.25%
Dec-10-25 09:20AM	Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit (GlobeNewswire)
Nov-20-25 07:02AM	Ocugen CEO to Present at NobleCon21-Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference (GlobeNewswire)
Nov-09-25 08:00PM	Ocugen Inc (OCGN) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Nov-05-25 10:55AM	Ocugen (OCGN) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
09:49AM	Ocugen: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Ocugen Provides Business Update with Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-23-25 07:30AM	Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-02-25 07:30AM	Ocugen to Present at Industry and Investor Conferences in October 2025 (GlobeNewswire) +5.36%
Sep-15-25 07:04PM	Why Ocugen Stock Zoomed 12% Higher Today (Motley Fool) +12.15%
06:03AM	Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea (GlobeNewswire)
Sep-02-25 07:02AM	Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025 (GlobeNewswire)
Aug-26-25 12:00PM	Ocugen (OCGN) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-13-25 06:27AM	Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST-Modifier Gene Therapy for Stargardt Disease (GlobeNewswire)
Aug-12-25 03:45PM	Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants (GlobeNewswire) +5.03%
Aug-08-25 05:03PM	Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants (GlobeNewswire)
Aug-02-25 03:07AM	Ocugen Inc (OCGN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Aug-01-25 09:35AM	Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
08:33AM	Ocugen: Q2 Earnings Snapshot (Associated Press Finance)
08:25AM	Ocugen Provides Business Update with Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-21-25 07:30AM	Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team (GlobeNewswire)
07:17AM	Ocugen doses first subject in trial of modifier gene therapy candidate (Clinical Trials Arena)
Jul-18-25 07:02AM	Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST-Novel Modifier Gene Therapy Candidate for Stargardt Disease (GlobeNewswire)
Jul-17-25 06:30AM	Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results (GlobeNewswire)
Jun-24-25 01:07PM	Carisma Therapeutics, OrthoCellix enter definitive merger agreement (TipRanks) +5.49%
Jun-23-25 07:30AM	Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases (GlobeNewswire) -7.44%
Jun-17-25 07:49AM	FDA clears Ocugens IND amendment for trial of Stargardt disease treatment (Clinical Trials Arena) -6.03%
Jun-16-25 07:02AM	Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST-Modifier Gene Therapy Candidate for Stargardt Disease (GlobeNewswire)
Jun-11-25 07:30AM	Ocugen To Present at BIO International Convention 2025 (GlobeNewswire)
Jun-05-25 07:02AM	Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea (GlobeNewswire) +7.41%
May-27-25 07:02AM	Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST-Modifier Gene Therapy for the Treatment of Stargardt Disease (GlobeNewswire)
May-10-25 03:04AM	Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ... (GuruFocus.com)
May-09-25 08:07AM	Ocugen: Q1 Earnings Snapshot (Associated Press Finance)
08:01AM	Ocugen Provides Business Update with First Quarter 2025 Financial Results (GlobeNewswire)
May-02-25 08:00AM	Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 07:30AM	Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress (GlobeNewswire)
Apr-16-25 10:01AM	Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1? (Insider Monkey) -6.53%
Apr-08-25 08:02AM	Ocugen to Present at the 2025 Cell & Gene Meeting on the Med (GlobeNewswire) -10.17%
Mar-26-25 08:50AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Mar-19-25 06:18AM	Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200 (Clinical Trials Arena) +6.31%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Musunuri Shankar	Chief Executive Officer	Oct 09 '26	Sale	0.95	468,727	445,291	4,018,470	Oct 13 09:07 PM
Musunuri Shankar	Chief Executive Officer	Oct 09 '26	Sale	0.95	57,264	54,401	1,030,771	Oct 13 09:07 PM
Shankar Musunuri	Officer	Oct 09 '26	Proposed Sale	0.95	525,991	497,965		Oct 09 06:15 PM
Musunuri Shankar	Chief Executive Officer	Sep 09 '26	Sale	1.12	468,727	524,974	4,487,197	Sep 11 09:13 PM
Musunuri Shankar	Chief Executive Officer	Sep 09 '26	Sale	1.12	57,264	64,136	1,088,035	Sep 11 09:13 PM
Shankar Musunuri	Officer	Sep 09 '26	Proposed Sale	1.12	525,991	589,741		Sep 09 04:30 PM
Johnson-Greene Treerita Essali	Chief Financial Officer	Jun 15 '26	Buy	1.23	21,000	25,830	521,000	Jun 17 04:13 PM
Zhang Junge	Director	Apr 01 '26	Option Exercise	0.79	194,134	154,303	1,359,316	Apr 02 09:26 PM

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Ph.D.Dr. Shankar Musunuri M.B.A.

Chief Scientific Officer and Head of Research & DevelopmentDr. Arun Upadhyay Ph.D.

CFO & Principal Accounting OfficerMs. Rita Johnson-Greene M.B.A.

Executive Vice President of OperationsMr. Paul Staid

General CounselJohn Kouch J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCGN

Ocugen Inc

Upgrade your Finviz experience